BACKGROUND: Patients with advanced breast cancer positive for human epidermal growth factor receptor 2 (HER2) are at high risk for brain metastasis (BM). The prevalence and significance of expression of HER2 and its truncated form p95HER2 (p95) in BM is unknown. METHODS: Seventy-five pairs of formalin-fixed paraffin-embedded samples from matched primary breast cancers (PBCs) and BM were assayed for quantitative p95 and HER2-total (H2T) protein expression using the p95 VeraTag and HERmark assays, respectively. RESULTS: There was a net increase in p95 and H2T expression in BM relative to the matched PBC (median 1.5-fold, P = .0007 and 2.1-fold, P < .0001, respectively). Cases with H2T-positive tumors were more likely to have the largest (≥5-fold) increase in p95 (odds ratio = 6.3, P = .018). P95 positivity in PBC correlated with progression-free survival (hazard ratio [HR] = 2.2, P = .013), trended with shorter time to BM (HR = 1.8, P = .070), and correlated with overall survival (HR = 2.1, P = .042). P95 positivity in BM correlated with time to BM (HR = 2.0, P = .016) but did not correlate with overall survival from the time of BM diagnosis (HR = 1.2, P = .61). CONCLUSIONS: This is the first study of quantitative p95 and HER2 expression in matched PBC and BM. BM of breast cancer shows significant increases in expression of both biomarkers compared with matched PBC. These data provide a rationale for future correlative studies on p95 and HER2 levels in BM.
BACKGROUND:Patients with advanced breast cancer positive for human epidermal growth factor receptor 2 (HER2) are at high risk for brain metastasis (BM). The prevalence and significance of expression of HER2 and its truncated form p95HER2 (p95) in BM is unknown. METHODS: Seventy-five pairs of formalin-fixed paraffin-embedded samples from matched primary breast cancers (PBCs) and BM were assayed for quantitative p95 and HER2-total (H2T) protein expression using the p95 VeraTag and HERmark assays, respectively. RESULTS: There was a net increase in p95 and H2T expression in BM relative to the matched PBC (median 1.5-fold, P = .0007 and 2.1-fold, P < .0001, respectively). Cases with H2T-positive tumors were more likely to have the largest (≥5-fold) increase in p95 (odds ratio = 6.3, P = .018). P95 positivity in PBC correlated with progression-free survival (hazard ratio [HR] = 2.2, P = .013), trended with shorter time to BM (HR = 1.8, P = .070), and correlated with overall survival (HR = 2.1, P = .042). P95 positivity in BM correlated with time to BM (HR = 2.0, P = .016) but did not correlate with overall survival from the time of BM diagnosis (HR = 1.2, P = .61). CONCLUSIONS: This is the first study of quantitative p95 and HER2 expression in matched PBC and BM. BM of breast cancer shows significant increases in expression of both biomarkers compared with matched PBC. These data provide a rationale for future correlative studies on p95 and HER2 levels in BM.
Authors: Nichon L Grupka; Kelly C Lear-Kaul; Bette K Kleinschmidt-DeMasters; Meenakshi Singh Journal: Arch Pathol Lab Med Date: 2004-09 Impact factor: 5.534
Authors: Susanne Taucher; Margaretha Rudas; Robert M Mader; Michael Gnant; Emanuel Sporn; Peter Dubsky; Sebastian Roka; Thomas Bachleitner; Florian Fitzal; Daniela Kandioler; Catharina Wenzel; Günther G Steger; Martina Mittlböck; Raimund Jakesz Journal: Breast Cancer Res Treat Date: 2003-12 Impact factor: 4.872
Authors: Carsten Denkert; Jens Huober; Sibylle Loibl; Judith Prinzler; Ralf Kronenwett; Silvia Darb-Esfahani; Jan C Brase; Christine Solbach; Keyur Mehta; Peter A Fasching; Bruno V Sinn; Knut Engels; Mattea Reinisch; Martin-Leo Hansmann; Hans Tesch; Gunter von Minckwitz; Michael Untch Journal: Breast Cancer Res Date: 2013-02-07 Impact factor: 6.466
Authors: Huan Cheng; Yalai Bai; William Sikov; Natalie Sinclair; Veerle Bossuyt; Maysa M Abu-Khalaf; Lyndsay N Harris; David L Rimm Journal: BMC Cancer Date: 2014-05-08 Impact factor: 4.430
Authors: Deepak Kanojia; Irina V Balyasnikova; Ramin A Morshed; Richard T Frank; Dou Yu; Lingjiao Zhang; Drew A Spencer; Julius W Kim; Yu Han; Dihua Yu; Atique U Ahmed; Karen S Aboody; Maciej S Lesniak Journal: Stem Cells Date: 2015-08-11 Impact factor: 6.277
Authors: Chi-Chih Kang; Toby M Ward; Jessica Bockhorn; Courtney Schiffman; Haiyan Huang; Mark D Pegram; Amy E Herr Journal: NPJ Precis Oncol Date: 2018-03-22
Authors: Sherona R Sirkisoon; Richard L Carpenter; Tadas Rimkus; Lance Miller; Linda Metheny-Barlow; Hui-Wen Lo Journal: Front Biosci (Elite Ed) Date: 2016-01-01
Authors: Renata Duchnowska; Rafał Pęksa; Barbara Radecka; Tomasz Mandat; Tomasz Trojanowski; Bożena Jarosz; Bogumiła Czartoryska-Arłukowicz; Wojciech P Olszewski; Waldemar Och; Ewa Kalinka-Warzocha; Wojciech Kozłowski; Anna Kowalczyk; Sherene Loi; Wojciech Biernat; Jacek Jassem Journal: Breast Cancer Res Date: 2016-04-27 Impact factor: 6.466